Clinical Trials
4 trialsNCT04624204 2026-05-26
MK 7339-013
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04948333 2026-03-18
Asciminib Treatment Optimization in ≥ 3rd Line CML-CP
Novartis
Phase 3 Completed
NCT06082635 2025-05-18
TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)
Shenzhen TargetRx Co., Ltd.
Phase 3 Active not recruiting
NCT02627677 2021-11-26
OPTIC-2L
Takeda
Phase 3 Terminated